Drugs Made In America Acquisition (DMAA) Competitors

In the previous week, Abacus Global Management had 3 more articles in the media than Drugs Made In America Acquisition. MarketBeat recorded 3 mentions for Abacus Global Management and 0 mentions for Drugs Made In America Acquisition. Abacus Global Management's average media sentiment score of 0.46 beat Drugs Made In America Acquisition's score of 0.00 indicating that Abacus Global Management is being referred to more favorably in the media.

Abacus Global Management has a net margin of 15.63% compared to Drugs Made In America Acquisition's net margin of 0.00%. Abacus Global Management's return on equity of 20.02% beat Drugs Made In America Acquisition's return on equity.

Abacus Global Management has a beta of 0.06, indicating that its stock price is 94% less volatile than the broader market. Comparatively, Drugs Made In America Acquisition has a beta of 0.01, indicating that its stock price is 99% less volatile than the broader market.

Abacus Global Management currently has a consensus target price of $10.00, suggesting a potential downside of 15.59%. Given Abacus Global Management's stronger consensus rating and higher probable upside, research analysts plainly believe Abacus Global Management is more favorable than Drugs Made In America Acquisition.

Abacus Global Management has higher revenue and earnings than Drugs Made In America Acquisition.

Kodiak AI has a consensus target price of $12.50, suggesting a potential upside of 134.96%. Given Kodiak AI's stronger consensus rating and higher possible upside, analysts clearly believe Kodiak AI is more favorable than Drugs Made In America Acquisition.

72.9% of Kodiak AI shares are held by institutional investors. 0.9% of Drugs Made In America Acquisition shares are held by insiders. Comparatively, 28.4% of Kodiak AI shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Drugs Made In America Acquisition has higher earnings, but lower revenue than Kodiak AI.

Drugs Made In America Acquisition has a beta of 0.01, meaning that its stock price is 99% less volatile than the broader market. Comparatively, Kodiak AI has a beta of 0.4, meaning that its stock price is 60% less volatile than the broader market.

In the previous week, Kodiak AI had 8 more articles in the media than Drugs Made In America Acquisition. MarketBeat recorded 8 mentions for Kodiak AI and 0 mentions for Drugs Made In America Acquisition. Drugs Made In America Acquisition's average media sentiment score of 0.00 beat Kodiak AI's score of -0.09 indicating that Drugs Made In America Acquisition is being referred to more favorably in the media.

Empire State Realty Trust has a beta of 1.35, meaning that its stock price is 35% more volatile than the broader market. Comparatively, Drugs Made In America Acquisition has a beta of 0.01, meaning that its stock price is 99% less volatile than the broader market.

In the previous week, Empire State Realty Trust had 2 more articles in the media than Drugs Made In America Acquisition. MarketBeat recorded 2 mentions for Empire State Realty Trust and 0 mentions for Drugs Made In America Acquisition. Empire State Realty Trust's average media sentiment score of 0.66 beat Drugs Made In America Acquisition's score of 0.00 indicating that Empire State Realty Trust is being referred to more favorably in the media.

Empire State Realty Trust has higher revenue and earnings than Drugs Made In America Acquisition.

Empire State Realty Trust has a net margin of 5.09% compared to Drugs Made In America Acquisition's net margin of 0.00%. Empire State Realty Trust's return on equity of 2.19% beat Drugs Made In America Acquisition's return on equity.

Empire State Realty Trust currently has a consensus price target of $5.92, suggesting a potential upside of 3.89%. Given Empire State Realty Trust's stronger consensus rating and higher possible upside, analysts plainly believe Empire State Realty Trust is more favorable than Drugs Made In America Acquisition.

67.1% of Empire State Realty Trust shares are held by institutional investors. 15.2% of Empire State Realty Trust shares are held by company insiders. Comparatively, 0.9% of Drugs Made In America Acquisition shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

UP Fintech has higher revenue and earnings than Drugs Made In America Acquisition.

In the previous week, UP Fintech had 6 more articles in the media than Drugs Made In America Acquisition. MarketBeat recorded 6 mentions for UP Fintech and 0 mentions for Drugs Made In America Acquisition. UP Fintech's average media sentiment score of 0.24 beat Drugs Made In America Acquisition's score of 0.00 indicating that UP Fintech is being referred to more favorably in the news media.

UP Fintech has a consensus price target of $9.23, suggesting a potential upside of 101.58%. Given UP Fintech's stronger consensus rating and higher possible upside, analysts clearly believe UP Fintech is more favorable than Drugs Made In America Acquisition.

UP Fintech has a net margin of 17.64% compared to Drugs Made In America Acquisition's net margin of 0.00%. UP Fintech's return on equity of 13.90% beat Drugs Made In America Acquisition's return on equity.

Drugs Made In America Acquisition has a beta of 0.01, suggesting that its stock price is 99% less volatile than the broader market. Comparatively, UP Fintech has a beta of 0.45, suggesting that its stock price is 55% less volatile than the broader market.

9.0% of UP Fintech shares are held by institutional investors. 0.9% of Drugs Made In America Acquisition shares are held by insiders. Comparatively, 50.9% of UP Fintech shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.